Abstracts tagged "osteoporosis"

Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Salman Mahmood¹, Yuanyuan Ji ², Yi Peng ² and Zaki Abou Zahr ¹, ¹Hennepin Healthcare, Minneapolis, MN, ²Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN
Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
Abstract Number: 1167 • 2019 ACR/ARP Annual Meeting
To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?
caroline Morizot¹, Marine Fauny ², Edem Allado ³, Frank Verhoeven ⁴, Eliane Albuisson ⁵, Astrid Pinzano-Watrin ⁶, Isabelle Chary-Valckenaere ⁵ and Damien Loeuille ⁷, ¹Department Of rheumatology, Vandoeuvre les Nancy, Lorraine, France, ²CHU Nancy, Vandoeuvre, France, ³CHRU Nancy, VANDOEUVRE, France, ⁴Univeristy of Franche comté, Besancon, France, ⁵Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, ⁶IMoPA. UMR 7365 CNRS, Vandoeuvre, France, ⁷Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France
Background/Purpose: Spine ankylosis is a risk factor of osteoporosis and mortality in ankylosing spondylitis (AS). Recently, thoracic-abdomino-pelvic CT (TAP-CT) has demonstrated its ability to screen…
Abstract Number: 2213 • 2019 ACR/ARP Annual Meeting
Evaluation of Factors Associated with Bone Structure in an SLE Cohort Measured by Clinical 3T MRI and DEXA
Amit Saxena¹, Peter Izmirly ², Jill Buyon ², Stephen Honig ², Xiaoliu Zhang ³, Punam Saha ⁴, H. Michael Belmont ⁵ and Gregory Chang ², ¹New York University School of Medicine, New York, NY, ²NYU School of Medicine, New York, ³University of Iowa, Iowa City, ⁴University of Iowa Healthcare, Iowa City, ⁵New York University School of Medicine, Ney York
Background/Purpose: Osteoporosis and bone fractures are a frequent cause of morbidity in systemic lupus erythematosus (SLE), and are felt to be related both to disease…
Abstract Number: 2730 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Paul Miller¹, Arkadi Chines ², Ben-Hur Albergaria ³, Evelien Gielen ⁴, Bente Langdahl ⁵, Akimitsu Miyauchi ⁶, Mark Vanderkelen ⁷, Cassandra Milmont ², Judy Maddox ² and Jonathan Adachi ⁸, ¹Colorado Center for Bone Research at Panorama Orthopedics and Spine Center, Golden, CO, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of Espirito Santo, Vitória, Brazil, ⁴Gerontology and Geriatrics, Department of Chronic Diseases, Metabolism and Aging, KU Leuven & Center for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷UCB Pharma, Brussels, Belgium, ⁸McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose: Osteoporosis and renal insufficiency are coexisting disease states in a substantial proportion of postmenopausal women. Since bisphosphonates are generally contraindicated in patients with estimated…
Abstract Number: 1192 • 2019 ACR/ARP Annual Meeting
Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital
Hiroki Ozawa¹, Sho Fukui ¹, Genki Kidoguchi ¹, Takehiro Nakai ², Satoshi Kawaai ¹, Ayako Koido ¹, Yukihiko Ikeda ¹, Masei Suda ¹, Haruyuki Yanaoka ¹, Hisanori Shimizu ¹, Hiromichi Tamaki ¹, Tokutaro Tsuda ¹, Mitsumasa Kishimoto ³, Kenichi Yamaguchi ¹ and Masato Okada ¹, ¹St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Japan, ²St.Luke International Hospital Immuno-Rheumatology Center, Tokyo, Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a common, preventable and treatable complication of glucocorticoid therapy. We defined quality indicator (QI) for GIOP and took a hospital-wide…
Abstract Number: 2214 • 2019 ACR/ARP Annual Meeting
Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients
Andrea Casabella ¹, Sabrina Paolino ², Alberto Sulli³, Elisa Alessandri ⁴, Vanessa Smith ⁵, Barbara Ruaro ⁶, Carmen Pizzorni ² and Maurizio Cutolo ⁷, ¹1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium, ⁶1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) patients show an increased risk of low bone mass as a result of multifactorial events: physical inactivity, persistent inflammation, low…
Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Eun Hye Park¹, Anna Shin ², Yaa-Hui Dong ³, You-Jung Ha ¹, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ⁶ and Eun Ha Kang ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
Abstract Number: 2215 • 2019 ACR/ARP Annual Meeting
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab
David Dempster¹, Peter Butler ², Mathias Bostrom ³, Jeri Nieves ¹, Hua Zhou ⁴, Li Chen ², Nicola Pannacciulli ², Rachel Wagman ² and Felicia Cosman ¹, ¹Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Hospital for Special Surgery, New York, NY, ⁴Helen Hayes Hospital, West Haverstraw, NY
Background/Purpose: Denosumab (DMAb) is a potent antiresorptive agent, but findings in non-human primates suggest that modeling-based bone formation (MBBF) may persist despite DMAb treatment (Ominsky…
Abstract Number: 1872 • 2019 ACR/ARP Annual Meeting
Worsening Trends in Osteoporosis Management in the Medicare Population: 2010-2014
Jeffrey Curtis¹, Shanette G. Daigle ², Setareh A. Williams ³, Richard Weiss ³, Yamei Wang ⁴ and Tarun Arora ², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Radius Health, Inc, Waltham, ⁴Radius Health, Inc, Waltham
Background/Purpose: Osteoporotic fractures are an important public health burden, and with an increasing aging population, the number of Americans at risk of fractures is projected…
Abstract Number: 2216 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
KEN NAKASEKO¹, ¹Department of Orthopaedic Surgery and Rheumatology Kuwana City Medical Center, kuwana mie, Japan
Background/Purpose: Bone mineral density (BMD) is used for the diagnosis of osteoporosis, predicting future fracture risk, and monitoring osteoporosis treatment. Osteoporosis is defined as BMD…
Abstract Number: 1873 • 2019 ACR/ARP Annual Meeting
Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Thomas Olenginski¹ and Karen Mackiewicz ², ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA
Background/Purpose: The morbidity and mortality of osteoporotic fractures threaten our aging population. Despite advances in new therapies for osteoporosis and technology to more effectively communicate, fewer…
Abstract Number: 2217 • 2019 ACR/ARP Annual Meeting
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Sima Terebelo¹, Madina Abduraimova ¹, Latoya Freeman-Beman ¹, Naureen Kabani ², Joshy Pathiparampil ¹, Olga Dvorkina ² and Ellen M Ginzler ³, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, ³State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Osteoporosis (OP) is a problem in the aging population. Patients with autoimmune disease are at increased risk for OP given their history of steroid…
Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Jacques Brown¹, Arkadi Chines ², Roland Chapurlat ³, Joseph Foldes ⁴, Xavier Nogues ⁵, Roberto Civitelli ⁶, Tobias De Villiers ⁷, Fabio Massari ⁸, Cristiano A. Zerbini ⁹, Wenjing Yang ², Chris Recknor ¹⁰ and Cesar Libanati ¹¹, ¹CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³INSERM UMR 1033, Université de Lyon, Lyon, France, ⁴Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁵IMIM Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹⁰United Osteoporosis Centers, Gainesville, GA, ¹¹UCB Pharma, Brussels, Belgium
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].